MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
Open Access
- 14 August 2014
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 124 (7) , 1183-1191
Abstract
Key Points: A high survival rate was seen in primary or secondary MF patients transplanted from matched related donors using the FluMel regimen. FluMel plus ATG in HSCT from unrelated donors for MF patients is associated with an increased risk of graft failure.Keywords
This publication has 48 references indexed in Scilit:
- Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosisHaematologica, 2012
- The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantationBlood, 2012
- Risk models predicting survival after reduced‐intensity transplantation for myelofibrosisBritish Journal of Haematology, 2012
- The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countriesBone Marrow Transplantation, 2011
- Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment StrategiesJournal of Clinical Oncology, 2011
- Outcome of Transplantation for MyelofibrosisTransplantation and Cellular Therapy, 2010
- Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor typeBone Marrow Transplantation, 2009
- Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)Haematologica, 2008
- Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantationBritish Journal of Haematology, 2008
- Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential ThrombocythemiaTransplantation and Cellular Therapy, 2007